financetom
Business
financetom
/
Business
/
Cintas to Post 'Modest' Fiscal Q2 Beat Due to Timing Headwinds, RBC Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cintas to Post 'Modest' Fiscal Q2 Beat Due to Timing Headwinds, RBC Says
Dec 16, 2024 12:17 PM

02:49 PM EST, 12/16/2024 (MT Newswires) -- Cintas ( CTAS ) is expected to post a "modest" beat when it reports fiscal Q2 earnings and revenue, with the magnitude of the beat expected lower versus prior quarters due to "high expectations" and "timing headwinds" tied to hurricanes and the presidential election, RBC Capital Markets said in an earnings preview Monday.

"We believe margin expansion will continue to be driven by Cintas' ( CTAS ) digital transformation, including the SmartTruck initiative, topline growth, and operational improvements," the investment firm said.

RBC expects a potential increase in the company's fiscal 2025 organic revenue growth guidance driven by favorable exposure to healthcare, hospitality, education, and government verticals, alongside operating leverage and share buybacks.

The company's revenue is more resilient to economic slowdowns compared to previous downturns because of greater service revenue mix, diversification into defensive verticals and strong cross-selling potential, according to the note.

Cintas ( CTAS ) is due to report fiscal Q2 results on Dec. 19.

The brokerage has a sector perform rating on Cintas' ( CTAS ) stock with a price target of $215.

Price: 212.63, Change: +1.41, Percent Change: +0.67

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
JBT Marel Settles Acquisition of Marel Shares, Begins Trading Under New Ticker Symbol
JBT Marel Settles Acquisition of Marel Shares, Begins Trading Under New Ticker Symbol
Jan 3, 2025
07:14 AM EST, 01/03/2025 (MT Newswires) -- JBT Marel (JBT, JBTM) said Friday it completed the settlement of its acquisition of all issued and outstanding shares of Marel that were tendered before the Dec. 20 expiration of its voluntary takeover offer. Shares of the combined company begin trading Friday under the new ticker symbol JBTM on the New York Stock...
Eton Pharmaceuticals Acquires Galzin to Expand Rare Disease Treatment Offerings
Eton Pharmaceuticals Acquires Galzin to Expand Rare Disease Treatment Offerings
Jan 3, 2025
07:19 AM EST, 01/03/2025 (MT Newswires) -- Eton Pharmaceuticals ( ETON ) said Friday that it acquired Galzin, an FDA-approved treatment for Wilson Disease. The company plans to begin US commercialization in Q1 2025 and offer personalized support through its Eton Cares program, including a $0 co-pay for eligible patients. Additionally, Eton said it acquired European rights to the product,...
Nu Skin Enterprises' Unit Sells Mavely Platform for $250 Million; Shares Rise
Nu Skin Enterprises' Unit Sells Mavely Platform for $250 Million; Shares Rise
Jan 3, 2025
07:18 AM EST, 01/03/2025 (MT Newswires) -- Nu Skin Enterprises ( NUS ) said Friday that its Rhyz unit has sold its Mavely marketing technology platform to Later, a portfolio company of Summit Partners, for $250 million. The purchase price was in cash and a minority equity stake in the combined Later/Mavely business, the company said. Shares of Nu Skin...
GSK Says China Approval Secured for Nucala to Treat Adults With Chronic Rhinosinusitis With Nasal Polyps
GSK Says China Approval Secured for Nucala to Treat Adults With Chronic Rhinosinusitis With Nasal Polyps
Jan 3, 2025
07:17 AM EST, 01/03/2025 (MT Newswires) -- GSK (GSK) said Friday that the China National Medical Products Administration has approved Nucala, or mepolizumab, as an add-on therapy with intranasal corticosteroids to treat adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps. The company said the approval was based on the results of a phase 3 trial of mepolizumab in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved